HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors
June 08 2023 - 8:31AM
Business Wire
Accomplished Medical Technology Leader and
Veteran Investor Bring Strategic Experience and Vision to Board
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector
electrocardiogram (VECG) platform intended for patient use at home,
today announced the appointment of Ken Nelson and Mark Strome to
its board of directors, effective as of June 5, 2023.
Ken Nelson, 48, is a 20-year digital health, medical device, and
remote patient monitoring executive and innovator. Over the past 10
years, Mr. Nelson has led commercial efforts for disruptive
technologies in the digital health, wearables, and cardiac remote
patient monitoring industries for three of the top four market
share players in cardiac digital health and remote patient
monitoring including BioTelemetry as VP of Sales, iRhythm as VP of
Sales & Marketing, and Bardy Diagnostics as Chief Commercial
Officer. Most recently, he served as Head of Digital Health,
Diagnostics, and Monitoring for Biotronik, a leading cardiac
digital health and medical device company. Mr. Nelson currently
serves as partner in the Medtech Advantage Fund, which has an
exclusive partnership with Medtech Innovator, the largest medtech
and digital health startup accelerator globally. In addition, he
serves as Chairman of the Board for CardiaCare, and is an active
board member in a handful of other disruptive cardiac digital
health and medtech startups. Ken earned a B.A. in Economics from
Vanderbilt University.
Mark Strome, 66, combines over 40 years of experience in the
investment management and securities industry. Mr. Strome is the
Founder, Chief Investment Officer, and Chairman at Strome
Investment Management, L.P. and Strome Group, Inc. Under his
leadership, Mr. Strome’s investment management company has managed
private placement hedge fund investments focusing on
non-traditional investments including commodities, currencies,
bankruptcy reorganizations, and numerous venture capital and
private equity investments. Previously, he was a Portfolio Manager
at Kayne Anderson. He has also been involved in the founding and
incubation of numerous publicly traded companies and several
successful private companies. These include Pulse Biosciences, and
iWood Studios, a company that creates original content for film and
TV. Mr. Strome has been a member of the Board of Directors of
multiple companies over the last three decades. He has served as a
Director at Endurance Ventures, National Water and Power, Eco-Duro
Corporation, NWP Services Corporation and Mobil Satellite Ventures.
He serves as Member of Advisory Board at Global Analytics, Inc. He
is a Trustee for New Roads School and Big Bear Foundation and
serves on the Board of Advisors of John Hopkins Medical Center.
“We are privileged to welcome two members with highly relevant
backgrounds to HeartBeam’s Board,” said Branislav Vajdic, Ph.D.,
HeartBeam CEO and Founder. “Ken brings extensive experience and
insights in cardiac digital health, remote patient monitoring, and
medical devices. His firsthand knowledge of our industry will be a
critical resource as we progress on our corporate goals. Mark is an
experienced investor and business executive who will help us expand
the breadth and depth of our reach as a Company, positioning us to
create additional value for our shareholders. Together, Ken and
Mark will contribute a wealth of expertise to the Board, adding to
the exceptional team that we have elected to guide us forward and
commercialize our business.”
Richard Ferrari, Executive Chairman of the Board of Directors,
added, “I look forward to working with both Mark and Ken as they
are outstanding additions to our board. I am confident that Mark
and Ken will offer valuable perspectives as we continue to position
the Company for the expected clearance and commercialization of the
HeartBeam AIMIGo™ 12-Lead 3D-vector electrocardiogram device.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform
intended for patient use at home. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to assess their cardiac symptoms quickly and easily, so
care can be expedited, if required. HeartBeam has two patented
products in development. HeartBeam AIMI™ is software for acute care
settings that provides a 3D comparison of baseline and symptomatic
12-lead ECG to more accurately identify a heart attack. HeartBeam
AIMIGo™ is the first and only credit card-sized 12-lead output ECG
device coupled with a smart phone app and cloud-based diagnostic
software system to facilitate remote evaluation of cardiac
symptoms. HeartBeam AIMI and HeartBeam AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005386/en/
Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
Media Contact:media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Oct 2023 to Oct 2024